‘Starving’ brain tumours to death
Exploring alterations in amino acid metabolism as novel therapeutic targets in paediatric glial tumours using advanced metabolomics methods
Reducing pain caused as a side effect of vincristine chemotherapy
Can we reduce or eliminate the sensory nerve damage caused by vincristine chemotherapy? Potential novel adjunct neuroprotective/analgesic therapies.
Phase II clinical trial: Can a new drug help treat relapsed or refractory (not responding to treatment) ALK+ anaplastic large cell lymphoma?
NIVO-ALCL - Phase II trial of nivolumab for paediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2)
Investigating novel drug combinations for acute myeloid leukaemia
Identifying Combination Therapies Targeting Apoptosis pathways in Paediatric AML (CAuSAL study)
Using repurposed drugs to repair the damage that causes acute myeloid leukaemia
Targeting mutant NRAS in paediatric AML
Repurposing existing drugs to improve outcomes in Ewing sarcoma
Repurposing of drugs targeting drug resistant self-renewing Ewing’s sarcoma cells to accelerate new treatments into clinical trials to improve outcomes.
Investigating the genetic pathways that control leukaemia growth
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia
Investigating the potential benefits of proton beam therapy for abdominal tumours
The use of proton beam therapy to improve outcomes in childhood abdominal tumours
Using an antibody 'smart bomb' to help the body fight cancer
Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with the anti-CD33 immunotoxin Gemtuzumab ozogamicin to restore anti-cancer immunity